MORRISVILLE, N.C. , Feb. 02, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 10,000 shares of Liquidia’s common stock to newly hired non-executive employees under the Liquidia Corporation 2022

Extends cash-runway through at least 2024 Provides flexibility to accelerate launch preparations timed with success in litigation MORRISVILLE, N.C. , Jan. 09, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) ( Liquidia or the Company) announced today that it has entered into a Revenue

Liquidia and Sandoz will collaborate with Mainbridge Health Partners to develop a new infusion pump Liquidia and Sandoz have also extended the term of their promotion agreement for Treprostinil Injection until 2032 MORRISVILLE, N.C. , Dec. 05, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:

Company to host webcast and conference call today at 8:30 a.m. ET MORRISVILLE, N.C. , Nov. 08, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the third quarter ended September 30, 2022 .

MORRISVILLE, N.C. , Nov. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022 . The company will host a conference call and webcast at 8:30 a.m.

MORRISVILLE, N.C. , Oct. 27, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that on October 26, 2022 , the Precedential Opinion Panel (POP) of the United States Patent and Trademark Office (USPTO) denied a request by United Therapeutics (UTC) to review the decision by

MORRISVILLE, N.C. , Oct. 17, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the presentation of data related to the investigational use of YUTREPIA™ (treprostinil) inhalation powder, previously referred to as LIQ861, at the CHEST 2022

District Court ruling was favorable on ‘066 patent and unfavorable on ‘793 patent All patent claims asserted have been found to be either invalid or not infringed by District Court or U.S. Patent Trial and Appeal Board (PTAB) PTAB decision to invalidate all claims of ‘793 patent is not affected

MORRISVILLE, N.C. , Aug. 22, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 7,000 shares of Liquidia’s common stock to newly hired non-executive employees under the Liquidia Corporation 2022

Company to host webcast and conference call today at 8:30 a.m. ET MORRISVILLE, N.C. , Aug. 11, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the second quarter ended June 30, 2022 .